Axsome insider buys 12,485 shares—signaling confidence despite a $183.72 dip. Explore what this means for investors and the company’s regulatory outlook.
Axsome CFO’s 12,000‑share buy‑sell cycle shows confident insider bets on the drug pipeline, with strategic 10(b)(5)(1) trades that signal long‑term optimism and clear liquidity management.